Drug poisoning deaths in England and Wales reached 5,565 in 2024. That is the highest total since records began in 1993, and a rise of 2.1% on the previous year. Behind that figure sits a much bigger shift. Emerging drug trends are changing what people actually take, and how professionals in family law can find out.

For those working in child safeguarding, this is not just a public health headline. Drug use can affect parenting capacity and risk within a home. The accuracy of what gets tested can shape a family’s future.

A shifting drug landscape

The UK drug market moves fast. New compounds appear, disappear, then resurface slightly altered. A parent might believe they took cannabis, diazepam, cocaine or heroin. In reality, the substance may contain something else entirely, such as a synthetic cannabinoid, fentanyl or a nitazene.

Novel psychoactive substances, or NPS, sit at the centre of these emerging drug trends. The term covers synthetic opioids, cannabinoids, benzodiazepines, stimulants and hallucinogens. Many mimic familiar illicit drugs. Some evade easy detection altogether.

Nitazenes offer a stark example. These synthetic opioids now drive a growing number of UK deaths. Dealers often mix them into heroin or cocaine, or sell them in place of it. Afghan opium production has fallen sharply, and heroin has become scarcer as a result. Synthetic opioids increasingly fill that gap, sometimes without the user ever knowing.

Synthetic cannabinoids follow a similar pattern. People often group them loosely under names such as spice, yet the compounds in circulation change constantly. Many carry far greater potency than cannabis. They can trigger confusion, agitation and collapse. Some vapes marketed as containing THC have turned out to contain synthetic cannabinoids instead, exposing users without their knowledge.

Stimulant type substances such as MDPHP add further complexity. So does the misuse of prescription medicines including pregabalin and gabapentin. Both can affect mood and sedation. Both can undermine a parent’s ability to engage consistently with services and assessments.

Why this matters for family court safeguarding

Family courts rely on evidence that is accurate and complete. Where substance misuse is alleged, judges need more than a simple yes or no. They need to know what has been used, how often, and what that means for risk. That evidence can shape contact arrangements, rehabilitation plans and final welfare decisions.

A narrow testing instruction can distort that picture. Professionals sometimes hold real concerns, drawn from presentation, police intelligence or patterns of behaviour. Standard testing may still offer no explanation. Often the reason is simple. The substance involved falls outside the routine panel.

Novel substances complicate the instructions themselves. Street names are inconsistent. The same label can refer to different compounds in different parts of the country. A parent describing what they took may genuinely not know its true composition. Professionals can end up working from incomplete information from the very start.

Why some laboratories fall behind

The core problem is simple. The illicit market moves faster than many testing systems can follow. A new substance typically needs time before laboratories can identify it, add it to reference libraries and validate it within accredited methods. That caution matters, but it means testing can lag behind the substances actually in circulation. It shows how quickly emerging drug trends can outpace testing capability.

The Office for National Statistics tracks this gap directly. It reports that the proportion of drug deaths with no specific substance information keeps rising. That gap matters just as much in family proceedings. Missing relevant drug use can carry lasting consequences for a child.

Not every laboratory tests for the same things. One provider may cover certain synthetic cannabinoids yet miss the ones currently most common. Another may test for older NPS compounds while overlooking newer ones. Assuming every forensic toxicology provider works from the same list can leave real gaps in the evidence.

Closing the testing gap

Forensic Testing Service, known as FTS, has built one of the more extensive accredited drug panels used in UK family proceedings. The court instruction guides FTS, which can identify more than 43 compounds alongside 15 stimulants and hallucinogens. It can also screen for a further 2,000 additional compounds, including novel psychoactive substances. The panel updates as new drug trends emerge.

Its testing includes ADB Butinaca, currently one of the most common synthetic cannabinoids in the UK, alongside pregabalin and gabapentin. FTS also tests for MDPHP, the active ingredient in the drug often called monkey dust. That substance has caused serious harm and several deaths in parts of the Midlands.

FTS reports only on the substances a court requests. It can flag where it identifies additional compounds, so professionals can request an addendum report if needed. Genuine uncertainty about what a parent may have used calls for a wider net. Screening across a much broader panel gives professionals a realistic chance of finding out, rather than relying on a list built around drugs that may no longer reflect the current market.

Its services carry ISO/IEC 17025 and Lab 51 UKAS accreditation. They meet Legal Aid Authority requirements. Laboratories typically produce reports within five days of a sample arriving.

What Emerging Drug Trends Mean for Families

Emerging drug trends keep reshaping the substances circulating across the UK. The gap between what people use and what professionals test for can widen quickly. For children whose safety depends on the court seeing an accurate picture, that gap is no technicality. It marks the difference between catching a risk early and missing it altogether.

The safest position for any family stays straightforward. Avoiding unknown or unregulated substances removes the uncertainty entirely. Testing strategies that keep pace with the changing drug landscape exist for one reason: to protect the children whose home life depends on getting that assessment right.

Source: dbrecoveryresources